M
Microbot Medical Inc.
MBOTCIK 0000883975NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-13.14M
Total Assets
$81.54M
Equity
$77.55M
Shares Out
67.16M
Op. Cash Flow
$-13.05M
Business
Microbot Medical Inc. is a clinical-stage medical device company developing next-generation robotic endoluminal surgical systems for minimally invasive procedures. It offers the LIBERTY® Endovascular Robotic Surgical System — a compact, fully disposable, remotely operated robot for maneuvering guidewires, catheters and over-the-wire devices — and the NovaCross® intraluminal revascularization product line acquired from Nitiloop. Key business activities include product research and development, preclinical and clinical testing, regulatory submissions and technology licensing. Microbot targets U.S., European and other international medical markets, pursuing commercialization through direct sales, distributors and strategic partnerships.
Summary from filing dated 2025-03-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development, net | −6 | −7 | −6 | −8 | −6 | |
| Sales, general and administrative | −8 | −5 | — | — | — | |
| Operating loss | −15 | −12 | −10 | −13 | −11 | |
| Financing income, net | 1 | 182,000 | 228,000 | 118,000 | 44,000 | |
| Other income | 316,000 | — | — | — | — | |
| Net loss | −13 | −11 | −11 | −13 | −11 | |
| Basic net loss per share | −0.29 | −0.73 | −1.05 | −1.81 | −1.59 | |
| Diluted net loss per share | −0.29 | −0.73 | −1.05 | −1.81 | — | |
| Basic weighted average common shares outstanding | 46 | 16 | 10 | 7 | 7 | |
| Diluted weighted average common shares outstanding | 46 | 16 | 10 | 7 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 4 | 3 | 2 | 2 | 13 | |
| Marketable securities | 75 | 2 | 4 | 6 | 2 | |
| Restricted cash | 2,000 | 49,000 | 49,000 | 77,000 | 87,000 | |
| Inventory | 584,000 | — | — | — | — | |
| Prepaid expenses and other current assets | 644,000 | 300,000 | 152,000 | 532,000 | 300,000 | |
| Total current assets | 80 | 6 | 8 | 9 | 16 | |
| Restricted cash | 59,000 | — | — | — | — | |
| Long-term deposit | 737,000 | — | — | — | — | |
| Property and equipment, net | 93,000 | 80,000 | 146,000 | 221,000 | 244,000 | |
| Operating right-of-use assets | 833,000 | 132,000 | 260,000 | 502,000 | 644,000 | |
| Total assets | 82 | 6 | 8 | 10 | 17 | |
| Accounts payable | 511,000 | 165,000 | — | 116,000 | 279,000 | |
| Lease liabilities | 296,000 | 70,000 | 191,000 | 283,000 | 278,000 | |
| Accrued liabilities | 3 | 2 | 1 | 2 | 1 | |
| Total current liabilities | 3 | 2 | 4 | 2 | 2 | |
| Long-term lease liabilities | 569,000 | 41,000 | 40,000 | 179,000 | 402,000 | |
| Total liabilities | 4 | 3 | 4 | 2 | 2 | |
| Commitments and contingencies | — | — | — | — | — | |
| Common stock; $0.01 par value; 120,000,000 and 60,000,000 shares authorized as of December 31, 2025 and 2024, respectively; 67,158,044 and 19,399,513 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 672,000 | 195,000 | 118,000 | 80,000 | 72,000 | |
| Additional paid-in capital | 181 | 94 | 84 | 76 | 70 | |
| Accumulated deficit | −104 | −91 | −80 | −69 | −56 | |
| Total shareholders equity | 78 | 4 | 5 | 7 | 14 | |
| Total liabilities and shareholders equity | 82 | 6 | 8 | 10 | 17 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation of property and equipment | 47,000 | 91,000 | 106,000 | 102,000 | 76,000 | |
| Interest income and unrealized gains from marketable securities, net | — | −1,000 | −160,000 | −12,000 | — | |
| Share-based compensation | 1 | 1 | 1 | 2 | 1 | |
| Inventory | −584,000 | — | — | — | — | |
| Prepaid expenses and other assets | −182,000 | 69,000 | 672,000 | 13,000 | 177,000 | |
| Accounts payable and accrued liabilities | 495,000 | 873,000 | — | — | — | |
| Change in long-term deposit | −737,000 | — | — | — | — | |
| Insurance recovery related to legal settlement and legal expenses received in cash | — | 1 | −1 | — | — | |
| Legal settlement paid in cash | — | −1 | — | — | — | |
| Net cash flows used in operating activities | −13 | −9 | −9 | −12 | −9 | |
| Purchase of property and equipment | −60,000 | −25,000 | −33,000 | −84,000 | −69,000 | |
| Proceeds from maturities of marketable securities | — | 3 | 9 | — | — | |
| Purchase of marketable securities | −83 | −5 | −10 | — | — | |
| Proceeds from sales of marketable securities | 11 | 4 | 3 | — | 3 | |
| Net cash flows (used in) provided by investing activities | −72 | 2 | 2 | −4 | 3 | |
| Issuance of common stock and warrants, net of issuance costs | 86 | 8 | 7 | 4 | — | |
| Exercise of options | 1,000 | — | — | — | — | |
| Net cash flows provided by financing activities | 86 | 8 | 7 | 4 | — | |
| Increase in cash, cash equivalents and restricted cash | 810,000 | 646,000 | −2,000 | −11 | −6 | |
| Issuance costs not paid | 101,000 | — | — | — | — | |
| Legal settlement settled through issuance of common stock | — | 1 | — | — | — | |
| Right-of-use assets obtained in exchange for lease liabilities | 893,000 | 98,000 | 50,000 | 103,000 | 69,000 | |
| Accrued bonus settled through grant of stock-option awards | — | 76,000 | — | — | — | |
| Deferred issuance costs | 30,000 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro